Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 9/20 | 0.35 |
| ▸ | JAK3 | P52333 | 9/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053272 | 0.78 | HTR3A (0.41) | DRD4BCHEACHEMAPTRAB9A | |
| SCHEMBL16053274 | 0.65 | MAPT (0.76) | DRD4BCHEACHEMAPTRAB9A | |
| SCHEMBL1701390 | 0.62 | L3MBTL1 (0.41) | ALDH1A1HSD17B10HPGD | |
| SCHEMBL11397558 | 0.60 | METAP2 (0.77) | MAPTRAB9AHPGD | |
| SCHEMBL24015604 | 0.59 | GCK (0.45) | CYP1A2 | |
| SCHEMBL26465261 | 0.59 | GCK (0.45) | CYP1A2 | |
| SCHEMBL24015591 | 0.59 | GCK (0.45) | CYP1A2 | |
| SCHEMBL16053273 | 0.59 | PLD1 (0.39) | DRD4MAPTRAB9AALDH1A1HSD17B10 | |
| SCHEMBL17611157 | 0.59 | MAPT (0.37) | DRD4MAPTRAB9AALDH1A1 | |
| SCHEMBL16053223 | 0.59 | NUDT1 (0.38) | DRD4MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | DRD4 4156/4885BCHE 4455/4885ACHE 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.